AI Portfolio Summary
In 2025 Q4, NEA Management Company, LLC maintained a portfolio of 30 distinct positions. The most significant new addition to the portfolio was LeonaBio, Inc., which now represents 0.18% of the total fund value. They heavily accumulated shares in Celcuity Inc., increasing their position by 64.9%. Conversely, NEA Management Company, LLC completely exited their position in OMADA HEALTH INC.
Total Positions
30
Quarter
2025 Q4
Top Holding
CELC (18.0%)
Top 10 Concentration
86.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-30 of 30
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CELC
Celcuity Inc.
|
Healthcare | 17.98% | 5.81% |
#1
5
Prev: #6
|
9.0 | 1,391,300 | 64.9% |
P
S
|
3,535,561 | $352,636,854 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RYTM
Rhythm Pharmace...
|
Healthcare | 15.88% | 16.13% |
#2
1
Prev: #1
|
6.5 | no change | no change |
P
S
|
2,909,956 | $311,481,690 | 2017 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
Arcellx, Inc.
|
Healthcare | 10.12% | 13.72% |
#3
1
Prev: #2
|
6.0 | no change | no change |
P
S
|
3,045,262 | $198,551,082 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
Trevi Therapeut...
|
Healthcare | 8.44% | 6.64% |
#4
1
Prev: #5
|
4.9 | no change | no change |
P
S
|
13,222,228 | $165,542,295 | 2019 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SVRA
Savara, Inc.
|
Healthcare | 7.52% | 4.79% |
#5
2
Prev: #7
|
4.5 | no change | no change |
P
S
|
24,471,264 | $147,561,722 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZBIO
Zenas BioPharma...
|
Healthcare | 6.52% | 3.33% |
#6
4
Prev: #10
|
5.1 | 789,500 | 28.9% |
P
S
|
3,523,219 | $127,928,082 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GLUE
Monte Rosa Ther...
|
Healthcare | 6.15% | 3.13% |
#7
4
Prev: #11
|
3.5 | no change | no change |
P
S
|
7,692,298 | $120,615,233 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MBX
MBX Biosciences...
|
Healthcare | 5.81% | 3.47% |
#8
1
Prev: #9
|
3.3 | no change | no change |
P
S
|
3,614,486 | $114,000,888 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COUR
Coursera, Inc.
|
Consumer Defensive | 4.83% | 8.27% |
#9
5
Prev: #4
|
2.9 | no change | no change |
P
S
|
12,867,769 | $94,706,780 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AUPH
Aurinia Pharmac...
|
Healthcare | 3.23% | 2.41% |
#10
5
Prev: #15
|
2.3 | no change | no change |
P
S
|
3,969,834 | $63,318,852 | 2014 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GOSS
Gossamer Bio, I...
|
Healthcare | 2.86% | 2.61% |
#11
3
Prev: #14
|
2.1 | no change | no change |
P
S
|
18,093,034 | $56,088,405 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRSP
CRISPR Therapeu...
|
Healthcare | 2.83% | 3.76% |
#12
4
Prev: #8
|
2.1 | no change | no change |
P
S
|
1,058,570 | $55,511,411 | 2016 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORIC
ORIC Pharmaceut...
|
Healthcare | 1.72% | 2.71% |
#13
Prev: #13
|
1.7 | no change | no change |
P
S
|
4,118,621 | $33,690,320 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHAT
Phathom Pharmac...
|
Healthcare | 1.66% | 1.27% |
#14
2
Prev: #16
|
1.7 | no change | no change |
P
S
|
1,960,169 | $32,519,204 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CVRX
CVRx, Inc.
|
Healthcare | 0.73% | 0.90% |
#15
4
Prev: #19
|
1.3 | no change | no change |
P
S
|
2,026,083 | $14,385,189 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
X4 Pharmaceutic...
|
—
|
Unknown | 0.66% | 0.42% |
#16
7
Prev: #23
|
2.8 | 1,000,000 | 44.8% |
P
S
|
3,233,743 | $12,934,972 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
CSBR
Champions Oncol...
|
Healthcare | 0.60% | 0.61% |
#17
3
Prev: #20
|
1.2 | no change | no change |
P
S
|
1,713,720 | $11,841,805 | 2015 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BDTX
Black Diamond T...
|
Healthcare | 0.55% | 0.93% |
#18
Prev: #18
|
1.2 | no change | no change |
P
S
|
4,448,757 | $10,810,480 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRRO
Korro Bio, Inc.
|
Healthcare | 0.45% | 2.87% |
#19
7
Prev: #12
|
1.2 | no change | no change |
P
S
|
1,090,793 | $8,737,252 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IVA
Inventiva SA
|
Healthcare | 0.35% | 0.46% |
#20
1
Prev: #21
|
1.1 | no change | no change |
P
S
|
1,462,586 | $6,801,025 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NKTX
Nkarta, Inc.
|
Healthcare | 0.34% | 0.41% |
#21
3
Prev: #24
|
1.1 | no change | no change |
P
S
|
3,568,781 | $6,602,245 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SNTI
Senti Bioscienc...
|
Healthcare | 0.20% | 0.29% |
#22
3
Prev: #25
|
1.1 | no change | no change |
P
S
|
3,775,615 | $3,926,640 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LONA
LeonaBio, Inc.
|
Healthcare | 0.18% | — |
#23
Prev: #—
|
3.6 | 464,398 | no change |
NEW
|
464,398 | $3,515,493 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYBX
Synlogic, Inc.
|
Healthcare | 0.17% | 0.27% |
#24
2
Prev: #26
|
1.1 | no change | no change |
P
S
|
2,922,772 | $3,273,505 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRKR
Marker Therapeu...
|
Healthcare | 0.12% | 0.08% |
#25
2
Prev: #27
|
1.0 | no change | no change |
P
S
|
1,625,678 | $2,422,260 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OKUR
OnKure Therapeu...
|
Healthcare | 0.07% | 0.07% |
#26
2
Prev: #28
|
1.0 | no change | no change |
P
S
|
478,548 | $1,387,789 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMA
ImageneBio, Inc...
|
Healthcare | 0.02% | 0.02% |
#27
2
Prev: #29
|
1.0 | no change | no change |
P
S
|
50,005 | $345,035 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OMDA
OMADA HEALTH IN...
|
Healthcare | 0.00% | 0.44% |
Sold All 😨
(Was: #22) |
0.0 | -364,115 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NEUE
NEUEHEALTH INC
|
Unknown | 0.00% | 1.00% |
Sold All 😨
(Was: #17) |
0.0 | -2,726,917 | -100.0% |
CLOSED
|
— | $— | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRNA
VERONA PHARMA P...
|
Unknown | 0.00% | 13.19% |
Sold All 😨
(Was: #3) |
0.0 | -2,252,994 | -100.0% |
CLOSED
|
— | $— | 2017 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-30 of 30 holdings